Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aethlon Medical (AEMD) Gains from Investment Securities (2016 - 2025)

Aethlon Medical (AEMD) has disclosed Gains from Investment Securities for 14 consecutive years, with $7073.0 as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Gains from Investment Securities rose 147.33% year-over-year to $7073.0, compared with a TTM value of $47490.0 through Dec 2024, up 1351.85%, and an annual FY2024 reading of $86466.0, up 302.34% over the prior year.
  • Gains from Investment Securities was $7073.0 for Q4 2024 at Aethlon Medical, up from $3832.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $35786.0 in Q2 2021 and bottomed at -$77477.0 in Q1 2022.
  • Average Gains from Investment Securities over 5 years is $8158.6, with a median of $9107.5 recorded in 2023.
  • The sharpest move saw Gains from Investment Securities skyrocketed 1235.51% in 2021, then tumbled 396.44% in 2022.
  • Year by year, Gains from Investment Securities stood at $31802.0 in 2020, then tumbled by 57.37% to $13557.0 in 2021, then plummeted by 158.81% to -$7973.0 in 2022, then crashed by 87.43% to -$14944.0 in 2023, then soared by 147.33% to $7073.0 in 2024.
  • Business Quant data shows Gains from Investment Securities for AEMD at $7073.0 in Q4 2024, $3832.0 in Q3 2024, and $5078.0 in Q2 2024.